DAB389IL-2 interleukin-2 receptor targeted fusion toxin data

SRGN announced that a Phase II trial of a four-week course of DAB389IL-2

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE